发明授权
US06338862B1 Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors 有权
使用cGMP特异性磷酸二酯酶5型抑制剂治疗性功能障碍的组合物和方法

  • 专利标题: Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
  • 专利标题(中): 使用cGMP特异性磷酸二酯酶5型抑制剂治疗性功能障碍的组合物和方法
  • 申请号: US09681362
    申请日: 2001-03-26
  • 公开(公告)号: US06338862B1
    公开(公告)日: 2002-01-15
  • 发明人: Sarfaraz K Niazi
  • 申请人: Sarfaraz K Niazi
  • 主分类号: A61K3578
  • IPC分类号: A61K3578
Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
摘要:
The inhibitors of cyclic guanosine monophosphate (cGMP) phosphodiesterases type 5 (cGMP-PDE5) such as sildenafil citrate (Viagra®) act by increasing the level of cGMP in sexual organs to produce enhanced blood flow and an erectile response of sexual organs. Though sildenafil citrate is a specific inhibitor of cGMP-PDE5, its effects on other body organs produce many side effects including fatalities. Described here is a method of combining cGMP-PDE5 inhibitors with natural sources of nutrients that instantly enhance the levels of endogenous cGMP and thus reduce the therapeutic dose and therefore the side effects of cGMP-PDE5 inhibitors. We have discovered that if sildenafil citrate, as a prototype of cGMP-PDE5, is combined with L-arginine, ginseng, vitamin B6, vitamin B12, and folic acid, all natural and safe ingredients, the dose requirements for sildenafil citrate can be reduced substantially. The specific composition described here assists in the action of sildenafil primarily by increasing the production of cGMP through modulation of nitric oxide pathway (L-arginine→nitric oxide→cGMP) and secondarily by having its own effect on improving blood circulation to sexual organs.
信息查询
0/0